Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request, 79347-79348 [2015-31936]

Download as PDF Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by February 2, 2016. Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Lee L. Zwanziger at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/Advisory Committees/AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: December 15, 2015. Jill Hartzler Warner, Associate Commissioner for Special Medical Programs. [FR Doc. 2015–31893 Filed 12–18–15; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request Health Resources and Services Administration, HHS. ACTION: Notice. AGENCY: In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the Health Resources and Services Administration (HRSA) has submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. DATES: Comments on this ICR should be received no later than January 20, 2016. mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:38 Dec 18, 2015 Jkt 238001 Submit your comments, including the Information Collection Request Title, to the desk officer for HRSA, either by email to OIRA_ submission@omb.eop.gov or by fax to 202–395–5806. FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance requests submitted to OMB for review, email the HRSA Information Collection Clearance Officer at paperwork@hrsa.gov or call (301) 594–4306. SUPPLEMENTARY INFORMATION: Information Collection Request Title: The Maternal, Infant, and Early Childhood Home Visiting Program Performance Measurement Information System. OMB No.: 0906–xxxx—NEW. Abstract: The Maternal, Infant, and Early Childhood Home Visiting Program (MIECHV), administered by HRSA in partnership with the Administration for Children and Families (ACF), supports voluntary, evidence-based home visiting services during pregnancy and to parents with young children up to kindergarten entry. States and territories (as well as nonprofit organizations selected to provide services in nonparticipating states and territories) are eligible to receive funding from the Home Visiting Program and have flexibility to tailor the program to serve the specific needs of their communities. Need and Proposed Use of the Information: HRSA will use the proposed information to demonstrate program accountability and continuously monitor and provide oversight to state and territory Home Visiting Program grantees. The information will also be used to provide quality improvement guidance and technical assistance to grantees and help inform the development of early childhood systems at the national, state, and local level. HRSA is seeking to collect demographic, service utilization, and select clinical indicators for participants enrolled in home visiting services. In addition, HRSA will collect a set of standardized performance and system outcome indicators that correspond with the statutorily identified benchmark areas. Demographic, Service Utilization, and Clinical Indicators Data: These data will describe the population served by the Home Visiting Program, including the unduplicated count of the number of participants and participant groups by race and ethnicity. These data will provide other socio-demographic ADDRESSES: PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 79347 characteristics of program participants and their utilization of services, such as program retention. Additionally, these data will describe several select clinical indicators of program participants, such as a child’s usual source of medical care. This information will be collected from participants at enrollment in home visiting services and aggregated and reported to HRSA by state/territory grantees once annually. Performance and System Outcome Benchmark Data: These data constitute a discrete set of standardized performance and system outcome indicators that correspond with the statutorily identified benchmark areas. These data will provide aggregate totals, percentages, and rates for performance and system outcome indicators that are salient to the Home Visiting Program, home visiting services more generally, and the at-risk populations served. These data will be collected from participants based on the appropriate measurement period defined for each measure and aggregated and reported to HRSA by state/territory grantees once annually. This information will be used to demonstrate accountability with legislative and programmatic requirements. It will also be used to monitor and provide continued oversight for grantee performance and to target technical assistance resources to grantees. In the future, it is anticipated that Home Visiting Program funding decisions may be allocated based on grantee performance, including on benchmark performance areas. Likely Respondents: Home Visiting Program grantees. Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below. E:\FR\FM\21DEN1.SGM 21DEN1 79348 Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Number of respondents Form name Number of responses per respondent Total responses Average burden per response (in hours) Total burden hours Form 1: Demographic, Service Utilization, and Clinical Indicators Data .................................................................... Form 2: Performance and System Outcome Benchmark Data .................................................................................. 56 1 56 425 23,800 56 1 56 425 23,800 Total .............................................................................. 56 ........................ 56 ........................ 47,600 Jackie Painter, Director, Division of the Executive Secretariat. [FR Doc. 2015–31936 Filed 12–18–15; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: Fluorescent Nanodiamonds as Fiducial Markers for Microscopy Description of Technology The invention relates to fluorescent nanodiamonds (FNDs) and their uses as fiducial markers for microscopy. FNDs are bright fluorescent probes that do not blink or bleach and have broad VerDate Sep<11>2014 17:38 Dec 18, 2015 Jkt 238001 fluorescence excitation and emission peaks. The fluorescence intensity can be readily controlled by the size of the FND, the number of fluorescent centers produced in the nanodiamonds, or in situ through the application of a weak magnetic field. The particular advantage of the FND compositions of this invention are that they are particularly useful for extended imaging of a single sample over time periods that can be as long as a week or more. In an exemplary embodiment, FNDs are immobilized in a substrate that are coated with an inert top coating, like silicon dioxide, or transparent polymer (e.g. poly-L-lysine, poly-L-arginine, or siloxanes). Generally, any suitable methods known for surface functionalization of the substrate can be used to make the composition. In another aspect of this invention, the inventors designed software for super-resolution imaging correction method is employed to precisely determine the position coordinates of each of a set of FNDs in a plurality of images by using Gaussian fitting of the point spread function comprises each of the FNDs in the plurality of images. The calculated correction is then used to displace each image to align the coordinates of the FNDs. The positions of the FNDs can be tracked with sub-nanometer precision and residual drift can be reduced to the nanometer scale over hundreds of hours of tracking. Potential Commercial Applications • Fluorescent Microscopy • Super-resolution microscopy • Correlative imaging techniques combing fluorescence microscopy with electron, x-ray, or atomic force microscopy imaging modalities Competitive Advantages • • • • • Non-blinking, Non-bleaching Chemically inert Chemically and physically stable Broad excitation Longevity Development Stage • In vitro data PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 Inventors • Keir Neuman, Ambika Bumb, Han Wen, Jennifer Hong and Susanta Sarkar (all of NHLBI) • Chang Yi, Lawrence Samelson, Asit Manna (all of NCI) Intellectual Property: HHS Reference No. E–217–2015/0–US–01 • US Provisional Patent Application 62/ 262,058 filed December 2, 2015. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. Collaborative Research Opportunity: The National Heart, Lung and Blood Institute seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate metallic nanoparticle vesicles for cancer phototherapy. For collaboration opportunities, please contact Vincent Kolesnitchenko, Ph.D. at kolesniv@nhlbi.nih.gov. Dated: December 15, 2015. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2015–31890 Filed 12–18–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Submission for OMB Review; 30-Day Comment Request; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery (NIAID) Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health, has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the Federal Register on October 1, 2015, 80 FR 59168 and allowed 60-days for SUMMARY: E:\FR\FM\21DEN1.SGM 21DEN1

Agencies

[Federal Register Volume 80, Number 244 (Monday, December 21, 2015)]
[Notices]
[Pages 79347-79348]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-31936]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Agency Information Collection Activities: Submission to OMB for 
Review and Approval; Public Comment Request

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In compliance with Section 3507(a)(1)(D) of the Paperwork 
Reduction Act of 1995, the Health Resources and Services Administration 
(HRSA) has submitted an Information Collection Request (ICR) to the 
Office of Management and Budget (OMB) for review and approval. Comments 
submitted during the first public review of this ICR will be provided 
to OMB. OMB will accept further comments from the public during the 
review and approval period.

DATES: Comments on this ICR should be received no later than January 
20, 2016.

ADDRESSES: Submit your comments, including the Information Collection 
Request Title, to the desk officer for HRSA, either by email to 
OIRA_submission@omb.eop.gov or by fax to 202-395-5806.

FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance 
requests submitted to OMB for review, email the HRSA Information 
Collection Clearance Officer at paperwork@hrsa.gov or call (301) 594-
4306.

SUPPLEMENTARY INFORMATION:
    Information Collection Request Title: The Maternal, Infant, and 
Early Childhood Home Visiting Program Performance Measurement 
Information System.
    OMB No.: 0906-xxxx--NEW.
    Abstract: The Maternal, Infant, and Early Childhood Home Visiting 
Program (MIECHV), administered by HRSA in partnership with the 
Administration for Children and Families (ACF), supports voluntary, 
evidence-based home visiting services during pregnancy and to parents 
with young children up to kindergarten entry. States and territories 
(as well as nonprofit organizations selected to provide services in 
non-participating states and territories) are eligible to receive 
funding from the Home Visiting Program and have flexibility to tailor 
the program to serve the specific needs of their communities.
    Need and Proposed Use of the Information: HRSA will use the 
proposed information to demonstrate program accountability and 
continuously monitor and provide oversight to state and territory Home 
Visiting Program grantees. The information will also be used to provide 
quality improvement guidance and technical assistance to grantees and 
help inform the development of early childhood systems at the national, 
state, and local level. HRSA is seeking to collect demographic, service 
utilization, and select clinical indicators for participants enrolled 
in home visiting services. In addition, HRSA will collect a set of 
standardized performance and system outcome indicators that correspond 
with the statutorily identified benchmark areas.
    Demographic, Service Utilization, and Clinical Indicators Data: 
These data will describe the population served by the Home Visiting 
Program, including the unduplicated count of the number of participants 
and participant groups by race and ethnicity. These data will provide 
other socio-demographic characteristics of program participants and 
their utilization of services, such as program retention. Additionally, 
these data will describe several select clinical indicators of program 
participants, such as a child's usual source of medical care. This 
information will be collected from participants at enrollment in home 
visiting services and aggregated and reported to HRSA by state/
territory grantees once annually.
    Performance and System Outcome Benchmark Data: These data 
constitute a discrete set of standardized performance and system 
outcome indicators that correspond with the statutorily identified 
benchmark areas. These data will provide aggregate totals, percentages, 
and rates for performance and system outcome indicators that are 
salient to the Home Visiting Program, home visiting services more 
generally, and the at-risk populations served. These data will be 
collected from participants based on the appropriate measurement period 
defined for each measure and aggregated and reported to HRSA by state/
territory grantees once annually.
    This information will be used to demonstrate accountability with 
legislative and programmatic requirements. It will also be used to 
monitor and provide continued oversight for grantee performance and to 
target technical assistance resources to grantees. In the future, it is 
anticipated that Home Visiting Program funding decisions may be 
allocated based on grantee performance, including on benchmark 
performance areas.
    Likely Respondents: Home Visiting Program grantees.
    Burden Statement: Burden in this context means the time expended by 
persons to generate, maintain, retain, disclose or provide the 
information requested. This includes the time needed to review 
instructions; to develop, acquire, install and utilize technology and 
systems for the purpose of collecting, validating and verifying 
information, processing and maintaining information, and disclosing and 
providing information; to train personnel and to be able to respond to 
a collection of information; to search data sources; to complete and 
review the collection of information; and to transmit or otherwise 
disclose the information. The total annual burden hours estimated for 
this ICR are summarized in the table below.

[[Page 79348]]



                                    Total Estimated Annualized Burden--Hours
----------------------------------------------------------------------------------------------------------------
                                                                                      Average
                                     Number of       Number of         Total        burden per     Total burden
            Form name               respondents    responses per     responses     response  (in       hours
                                                    respondent                        hours)
----------------------------------------------------------------------------------------------------------------
Form 1: Demographic, Service                  56               1              56             425          23,800
 Utilization, and Clinical
 Indicators Data................
Form 2: Performance and System                56               1              56             425          23,800
 Outcome Benchmark Data.........
                                 -------------------------------------------------------------------------------
    Total.......................              56  ..............              56  ..............          47,600
----------------------------------------------------------------------------------------------------------------


Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015-31936 Filed 12-18-15; 8:45 am]
BILLING CODE 4165-15-P